The Therapeutic Goods Administration (TGA) has issued infringement notices to Prime Medic Group Pty Ltd (Prime Medic) and an individual for the alleged unlawful advertising of weight loss medicines in contravention of the Therapeutic Goods Act 1989 (the Act).
One infringement notice for $19,800 was issued to Prime Medic, and one for $3,960 was issued to the individual. Prime Medic and the individual paid the infringement notices in January 2026.
Prime Medic operates an online telehealth platform offering consultations with doctors. It is alleged that Prime Medic advertised prescription-only weight loss medicines, Ozempic and Mounjaro, directly to consumers between at least January and July 2025.
Advertising prescription-only medicines directly to consumers is prohibited under the Act, as it can create inappropriate demand and undermine the relationship between patients and their treating health practitioner. Decisions about appropriate treatment options should be made by a patient, in consultation with their health professional.
It is also alleged that the advertising promoted the use of therapeutic goods for the treatment of serious diseases, conditions or disorders. Such references are known as restricted or prohibited representations and are not allowed to be included in advertising for therapeutic goods unless approval or permission is given by the TGA.
Health providers must understand their legal obligations before advertising therapeutic goods.
The TGA will continue to take action where serious non-compliance with the Act is identified in accordance with our regulatory compliance framework. This may include issuing infringement notices, directions and prevention notices, or civil or criminal proceedings.
If you suspect non-compliance in relation to therapeutic goods, or their advertising, you can report it to the TGA at any time.
